Shares of Rapport Therapeutics Inc. (RAPP) are trading at over a 30% discount to their 52-week high of $42.27, recorded last September, as the company advances its precision neuroscience pipeline, positioning it as a potential leader in epilepsy and a biotech story to watch.
Company Profile
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com